JP2022501336A5 - - Google Patents
Info
- Publication number
- JP2022501336A5 JP2022501336A5 JP2021514344A JP2021514344A JP2022501336A5 JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5 JP 2021514344 A JP2021514344 A JP 2021514344A JP 2021514344 A JP2021514344 A JP 2021514344A JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- optionally
- phytosterols
- seq
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731335P | 2018-09-14 | 2018-09-14 | |
| US62/731,335 | 2018-09-14 | ||
| US201862770024P | 2018-11-20 | 2018-11-20 | |
| US62/770,024 | 2018-11-20 | ||
| US201962881322P | 2019-07-31 | 2019-07-31 | |
| US62/881,322 | 2019-07-31 | ||
| PCT/US2019/051072 WO2020056304A1 (en) | 2018-09-14 | 2019-09-13 | Methods and compositions for treating cancer using mrna therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501336A JP2022501336A (ja) | 2022-01-06 |
| JP2022501336A5 true JP2022501336A5 (cg-RX-API-DMAC7.html) | 2022-09-20 |
| JP7556848B2 JP7556848B2 (ja) | 2024-09-26 |
Family
ID=68104746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514344A Active JP7556848B2 (ja) | 2018-09-14 | 2019-09-13 | mRNA治療薬を使用したがんを治療するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230081530A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3849589A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7556848B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113015540A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019338535A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3112781A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020056304A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3149386A1 (en) * | 2019-07-31 | 2021-02-04 | Modernatx, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
| AU2021270587A1 (en) * | 2020-05-14 | 2022-12-08 | Modernatx, Inc. | LNP compositions comprising an mRNA therapeutic and an effector molecule |
| CA3178965A1 (en) | 2020-05-15 | 2021-11-18 | Christian COBAUGH | Messenger rna encoding cas9 for use in genome-editing systems |
| WO2022010764A1 (en) * | 2020-07-06 | 2022-01-13 | Vivtex Corporation | Mucopenetrating formulations |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| CA3216873A1 (en) * | 2021-04-17 | 2022-10-22 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
| CN116406426A (zh) * | 2021-04-29 | 2023-07-07 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| WO2022240960A1 (en) | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
| US12251471B2 (en) * | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| CN114457054A (zh) * | 2022-02-24 | 2022-05-10 | 中国科学技术大学 | 一种cGAS mRNA的制备及作为免疫激活剂的应用 |
| WO2023192503A1 (en) * | 2022-03-30 | 2023-10-05 | The Johns Hopkins University | Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2023246840A1 (en) * | 2022-06-22 | 2023-12-28 | Wuhan Houxian Biopharmaceutical Co. Ltd. | Combination of il-12 and ox40l for cancer immunotherapy |
| CN119894525A (zh) * | 2022-07-15 | 2025-04-25 | 哈佛大学校长及研究员协会 | Mucispirillum组合物及其癌症治疗方法 |
| US20250387486A1 (en) * | 2022-08-09 | 2025-12-25 | Stemirna Therapeutics Co., Ltd. | Lipid composition |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| EP4649087A2 (en) | 2023-01-11 | 2025-11-19 | Engage Biologics Inc. | Non-viral expression systems and methods of use thereof |
| EP4470559A1 (en) * | 2023-06-02 | 2024-12-04 | Imgen-T-Srl | Combination containing an mrna vaccine and an immune modulating mrna for improved immunogenicity and efficacy |
| WO2025098508A1 (zh) * | 2023-11-10 | 2025-05-15 | 贝达药业股份有限公司 | 标记性多肽、治疗剂及其应用 |
| US20250177432A1 (en) * | 2023-12-04 | 2025-06-05 | Wuhan Houxian Biopharmaceutical Co. Ltd. | Rna molecules and compositions for cancer immunotherapy |
| WO2026044248A1 (en) * | 2024-08-23 | 2026-02-26 | Akagera Medicines, Inc. | Ionizable cationic lipids and lipid nanoparticle compositions |
| WO2026078565A1 (en) | 2024-10-10 | 2026-04-16 | Crispr Therapeutics Ag | Messenger rna encoding cas9 for use in genome-editing systems |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| EP2173378B1 (en) * | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| SG11201702295UA (en) | 2014-09-22 | 2017-04-27 | Intrexon Corp | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| AU2016251687C1 (en) * | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| SMT202200310T1 (it) * | 2015-12-23 | 2022-09-14 | Modernatx Inc | Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40 |
| RS63625B1 (sr) * | 2016-05-18 | 2022-10-31 | Modernatx Inc | Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba |
| CA3024509A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| PL3458083T3 (pl) * | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
| CN110267978A (zh) | 2016-10-07 | 2019-09-20 | 得克萨斯大学体系董事会 | 用于治疗癌症的表达膜锚定的il-12的t细胞 |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| US20190314291A1 (en) | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
-
2019
- 2019-09-13 JP JP2021514344A patent/JP7556848B2/ja active Active
- 2019-09-13 CA CA3112781A patent/CA3112781A1/en active Pending
- 2019-09-13 US US17/275,832 patent/US20230081530A1/en not_active Abandoned
- 2019-09-13 AU AU2019338535A patent/AU2019338535A1/en not_active Abandoned
- 2019-09-13 EP EP19780053.5A patent/EP3849589A1/en active Pending
- 2019-09-13 CN CN201980074987.2A patent/CN113015540A/zh active Pending
- 2019-09-13 WO PCT/US2019/051072 patent/WO2020056304A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Advances in immunotherapy for triple-negative breast cancer | |
| US8367628B2 (en) | Amphoteric liposome formulation | |
| JP2020520640A5 (cg-RX-API-DMAC7.html) | ||
| JP2023552195A5 (cg-RX-API-DMAC7.html) | ||
| CN104903450A (zh) | 寡核苷酸癌症疗法的给药和施用 | |
| JP5623016B2 (ja) | 癌治療法およびそれに用いる医薬組成物 | |
| EP3603748A1 (en) | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | |
| JP2020111589A (ja) | リポソーム製剤 | |
| Fan et al. | Lipid-based nanoparticles for cancer immunotherapy | |
| JP2022188159A (ja) | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 | |
| CN104884637A (zh) | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 | |
| CN108310378A (zh) | 一类新型免疫联体抗肿瘤创新药物的制备及其应用 | |
| JP2022525223A (ja) | sEphB4-HSA融合タンパク質を用いたがんの治療 | |
| KR20240158980A (ko) | 유기 화합물 | |
| TW202114647A (zh) | 用於治療具有高間質壓力的腫瘤受試者的癌症的小分子抑制劑 | |
| EP4031873A1 (en) | Quantitative spatial profiling for lag-3 antagonist therapy | |
| TWI760319B (zh) | 乳癌治療 | |
| WO2023161378A1 (en) | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof | |
| WO2009051712A1 (en) | Dnai amphoteric liposome formulation | |
| US20260000757A1 (en) | Combination therapy for lung cancer | |
| WO2007065017A2 (en) | Oligonucleotide cationic liposomal delivery system | |
| WO2020160409A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
| WO2022097634A1 (ja) | 血管新生依存性疾患治療に使用される医薬用組成物 | |
| CN116621966B (zh) | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 | |
| Le et al. | Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics |